Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMarin PharmaceuticalBMRN +1.64%76 Earnings Yield (Joel Greenblatt) % is 1.62% as of Jun. 2026, which is 1373% above its 10-year median of 0.11. GuruFocus rates BMRN with a GF Score™ of 76/100 and a GF Value™ of $83.53 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,346 Biotechnology companies, BioMarin Pharmaceutical ranks better than 81.58% on this metric.
BioMarin Pharmaceutical's Enterprise Value for the quarter that ended in Jun. 2026 was $14,386 Mil.
BioMarin Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $233 Mil. BioMarin Pharmaceutical's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 1.62%.
The historical rank and industry rank for BioMarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
BMRN'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5.49 Med: 0.11 Max: 8.7
Current: 1.44
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of BioMarin Pharmaceutical was 8.70%. The lowest was -5.49%. And the median was 0.11%.
BMRN's Earnings Yield (Joel Greenblatt) % is ranked better than 81.58% of 1346
companies
in the Biotechnology industry
Industry Median: -9.83
vs BMRN: 1.44
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. BioMarin Pharmaceutical's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 22.95%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
BioMarin Pharmaceutical Earnings Yield (Joel Greenblatt) % Related Terms
BioMarin Pharmaceutical Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for BioMarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioMarin Pharmaceutical's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
BioMarin Pharmaceuticals Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
BioMarin Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $233 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 1.62% mean?
BioMarin Pharmaceutical (BMRN) has a Earnings Yield (Joel Greenblatt) % of 1.62% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on BioMarin Pharmaceutical and its competitors. This is 1373% above median its historical median of 0.11. According to the industry distribution chart, BioMarin Pharmaceutical ranks #248 out of 1346 companies in the Biotechnology industry, placing it in the top 18.4%.
Is BioMarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % too high?
BioMarin Pharmaceutical's current Earnings Yield (Joel Greenblatt) % of 1.62% is 1373% above median its 10-year median of 0.11. Based on the distribution chart, BioMarin Pharmaceutical ranks #248 out of 1346 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % compare to TECH and CYTK?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #248 out of 1346 companies for Earnings Yield (Joel Greenblatt) %. This places BioMarin Pharmaceutical in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Earnings Yield (Joel Greenblatt) % is 1.62%, which is 1373% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (BMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.53, compared to a current price of $66.12 — trading 20.8% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 1.62%, which is 1373% above median its 10-year median of 0.11. BioMarin Pharmaceutical's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For BioMarin Pharmaceutical (BMRN), the current Earnings Yield (Joel Greenblatt) % is 1.62% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of $66.12 is trading 20.8% below its estimated GF Value™ of $83.53.
GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.
Key valuation signals for BMRN:
Earnings Yield (Joel Greenblatt) %: 1.62% (1373% above median its 10-year median of 0.11)
GF Value™: $83.53 vs. price of $66.12 (20.8% below fair value)
No single metric tells the full story. See the BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
76GF Score
Get the complete analysis for BMRN
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRN has been successfully added to your 
